41 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements … events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business
8-K
EX-99.1
COYA
Coya Therapeutics Inc
9 May 24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
4:20pm
. 2 LD IL-2 study in AD to inform on strategy and next steps for COYA 302 in AD
Presented data in March 2024 on immune system and Regulatory T Cell … capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations
8-K
EX-99.1
ulpq3ju2gps8zm98ex
19 Mar 24
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
8:21am
424B3
wic 54zzqcp4fyz
16 Jan 24
Prospectus supplement
4:06pm
S-3
olekcdaqn2w
4 Jan 24
Shelf registration
4:46pm
8-K
zk3zbsn1y016wuzn0
20 Dec 23
Departure of Directors or Certain Officers
8:35am
8-K
EX-99.1
wm01w0wbc4ja0r
20 Dec 23
Departure of Directors or Certain Officers
8:35am
8-K
kvrld2gceow2
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
y0p8yalpb o74lx42p
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
vf0xrp
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
8-K
EX-99.1
nro6pv20it7t7
21 Aug 23
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coya’s Board of Directors
5:01pm
8-K
EX-99.1
dsx2dhvw g6
8 Aug 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
7:05am
8-K
EX-99.1
vkqrwzci
12 Jun 23
Regulation FD Disclosure
5:01pm
DEF 14A
15d1r
19 May 23
Definitive proxy
4:31pm